Are you searching for effective medications to treat 'Cardiogenic Shock'? This comprehensive guide provides the latest information on medications-both generic and branded-that are essential for ...

Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

The recent study by Holger Thiele and colleagues1 offers an extensive meta-analysis on the use of mechanical circulatory support (MCS) in acute myocardial infarction-related cardiogenic shock (AMICS).

The following is a summary of "In-hospital outcomes of cardiogenic shock patients: A propensity score-matched nationwide ...

Treatment of cardiogenic shock is aimed at correcting the primary etiology and hemodynamic support with cardiac inotropes such as dobutamine or milrinone.

We thank our colleagues for their interest in our Article.1 We agree with Zaoqu Liu and colleagues that in addition to mortality assessment, quality of life and long-term functional outcomes are ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

“India’s population is greater than 1.4 billion people making it a part of our istaroxime strategic intellectual property plan,” said Jed Latkin, CEO of Windtree. “As we prepare for Phase 3 readiness ...

Addressing Unmet Needs Cardiogenic shock presents significant challenges for healthcare providers. Current medications are often fraught with limitations, leading to suboptimal outcomes.

WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...

Arrythmias in these patients can be caused by their underlying cardiac disease or by drugs used to treat ... prepare for Phase 3 readiness in cardiogenic shock, we plan to obtain intellectual ...